Anticoagulants are classified as high-risk medications, with their main adverse drug events (ADEs) being recurrent venous thromboembolism (VTE) and bleeding events.Postoperative colorectal cancer (CRC) patients exhibit a high probability of recurrent VTE and bleeding during anticoagulation therapy.The Medication Therapy Management (MTM) model will contribute to reducing ADEs associated with anticoagulants in CRC patients.
Patients with histologically confirmed CRC and symptomatic or incidental VTE who received anticoagulant treatment.
CRC patients with VTE treated with an anticoagulant for at least 3 moths.
None